FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4285087008> ?p ?o ?g. }

• W4285087008 abstract "Heterologous vaccination has been explored in small populations of solid organ transplant recipients (SOTRs),1-4 yet 38% of participants had persistently suboptimal response indicating potential role for further vaccine doses.1 The US CDC currently recommends immunocompromised adults who received an Ad26.COV2.S prime to receive one additional dose of SARS-CoV-2 mRNA vaccine, either BNT162b2 or mRNA-1273, followed by two mRNA vaccine boosters, although the efficacy of this strategy in immunocompromised persons is not known. We evaluated serial antispike antibody responses and reactogenicity among SOTRs who received two doses of mRNA vaccine following Ad26.COV2.S prime. Within our previously described observational cohort,2, 3 11 SOTRs reported an Ad26.COV2.S-prime (D1) followed by two doses of BNT162b2 (n = 5) or mRNA-1273 (n = 6). SOTRs who reported pre-D1 SARS-CoV-2 infection were excluded. The highest antibody results collected after doses 2 (D2) and 3 (D3) on the Roche Elecsys Anti-SARS-CoV-2 enzyme immunoassay (EIA) (antireceptor binding domain [RBD], negative < 0.8 U/ml) or EUROIMMUN EIA (anti-S1, negative < 1.1 AU) were compared. High-positive (anti-RBD ≥250 U/ml or anti-S1 ≥4 AU) levels were defined according to reported association with neutralization of wild-type virus.4 Post-D3 questionnaires on adverse events and side effects were collected. The study was approved by the Johns Hopkins IRB #00248540. Participants provided electronic informed consent. The median (interquartile range [IQR]) age was 58 (40, 67) years, five were female, seven were white, and nine were kidney-only transplant recipients. The median (IQR) time since transplant was 13 (5, 18) years. Peri-vaccination immunosuppressive regimens included calcineurin inhibitors (n = 7), antimetabolites (n = 11), steroids (n = 5), and mTOR inhibitors (n = 2); three reported triple immunosuppressant medications, defined as calcineurin inhibitor, antimetabolite, and steroid use. The median (IQR) time between D1 and D2 was 164 (75, 224) days, and between D2 and D3 was 28 (24, 80) days. Antispike seropositivity rates increased from 40%, 73%, to 91% after D1, D2, and D3, respectively. Of the three SOTRs that were seronegative post-D2, two converted to seropositive post-D3 (Table 1). High-positive titers were present in all 10 post-D3 sero-responders. More mRNA-1273-vaccinated than BNT162b2-vaccinated recipients had high-positive levels post-D2 (4/6 [67%] vs. 2/5 [40%]) and post-D3 (6/6 [100%] vs. 4/5 [80%]). The one persistently seronegative participant received BNT162b2 for D2 and D3. This participant was a 30-year-old female kidney-only transplant recipient who was 5 years post-transplant surgery and reported mycophenolate and tacrolimus as their only immunosuppression medications. The participant did not report any breakthrough infection. Eight SOTRs completed reactogenicity surveys, primarily characterized by mild or moderate local pain (n = 6), fatigue (n = 4), and/or headache (n = 4). No serious vaccine-associated reactions, including myocarditis, anaphylaxis, or vaccine-associated thrombosis, nor diagnosis of rejection, autoimmune or neurologic conditions, or need for hospitalization post-D3 were reported. One participant reported a home test-confirmed breakthrough SARS-CoV-2 infection 47 days after D3 (mRNA-1273). This patient was a 40-year-old female liver-only transplant recipient who was 0.4 years post-transplant surgery when she reported receiving Ad26.COV2.S. This participant reported triple immunosuppression therapy during the peri-vaccination period. The anti-RBD was 6.5 U/ml 20 days post-D2. No pre-infection sample was collected after D3, but their anti-RBD was >2500 U/ml 29 days post-breakthrough. The breakthrough case occurred in the second week of the US Omicron BA.1 wave, during which the Delta variant was co-circulating and represented the predominant variant per CDC monitoring.6 Symptoms included 7 days of mild cough and pharyngitis, during which the monoclonal antibody bamlanivimab/etesevimab was administered (on day 2). No oral antiviral medications were used. Despite suboptimal antibody response to the Ad26.COV2.S prime, two subsequent mRNA vaccines increased antibody titers to high levels for the majority of participants, with acceptable side effects. This series suggests that a heterologous vaccine regimen may be a reasonable option for SOTRs, though lack of sero-response, despite two mRNA boosters, suggests that some recipients may remain at risk for SARS-CoV-2 infection. Comparison of the humoral and cellular responses to three-dose heterologous versus homologous vaccination is needed. The authors thank the participants of the Johns Hopkins COVID-19 Transplant Vaccine Study, without whom this research could not be possible. They also thank the members of the study team, including Brian J. Boyarsky MD, PhD; Nicole F Hernandez, BS; Alexa Jefferis, BS; Ananda Thomas, BA; Faith Obilo; Letitia Thomas; Rivka Abedon; Chunyi Xia; Kim Hall; Mary Sears; Alex; Jonathan Susilo. They also thank Andrew H. Karaba, MD, PhD; and Ms. Yolanda Eby for project support and guidance. This research was made possible with the generous support of the Ben-Dov family and the Trokhan Patterson family. This work was supported by Grants T32DK007732 (Dr. Chang), 5T32DK007713 (Dr. Alejo), K01DK101677 (Dr. Massie), K01DK114388 (Dr. Levan), and K23DK115908 (Dr. Garonzik-Wang) from the National Institute of Diabetes and Digestive and Kidney Diseases; The ASTS Fryer Resident Scientist Award (Dr. Mitchell); K24AI144954 (Dr. Segev), K23AI157893 and 3U01AI138897-04S1 (Dr. Werbel) from the National Institute of Allergy and Infectious Disease. DLS has the following financial disclosures: consulting and/or speaking honoraria from Sanofi, Novartis, CSL Behring, Jazz Pharmaceuticals, Veloxis, Mallinckrodt, Thermo Fisher Scientific, Regeneron, Astra Zeneca, Caredx, Transmedics, Kamada, MediGo, Takeda/Shire, and Bridge to Life. RKA has study/grant support from Aicuris, Astellas, Chimerix, Merck, Oxford Immunotec, Qiagen, Regeneron, Takeda/Shire, and Vir/GSK and is an Associate Reviewer for Transplantation. MLL is the Social Media Editor for Transplantation and is a consultant for Takeda/Shire and Patients Like Me. The remaining authors of this manuscript have no conflicts of interest to disclose. Substantial contributions to the conception or design of the work: Amy Chang, Jonathan Mitchell, Jennifer L. Alejo, Teresa P.Y. Chiang, Aura T. Abedon, Jake D. Kim, Robin K. Avery, Aaron A.R. Tobian, Macey L. Levan, Daniel S. Warren, Jacqueline M. Garonzik-Wang, Allan B. Massie, Dorry L. Segev, and William A. Werbel. Acquisition, analysis, or interpretation of data for the work: Amy Chang, Jonathan Mitchell, Jennifer L. Alejo, Teresa P.Y. Chiang, Aura T. Abedon, Jake D. Kim, Robin K. Avery, Aaron A.R. Tobian, Macey L. Levan, Daniel S. Warren, Jacqueline M. Garonzik-Wang, Allan B. Massie, Dorry L. Segev, and William A. Werbel Drafting the work and revising it critically for important intellectual content: Amy Chang, Jonathan Mitchell, Jennifer L. Alejo, Teresa P.Y. Chiang, Aura T. Abedon, Jake D. Kim, Robin K. Avery, Aaron A.R. Tobian, Macey L. Levan, Daniel S. Warren, Jacqueline M. Garonzik-Wang, Allan B. Massie, Dorry L. Segev, and William A. Werbel. Final approval of the version to be published: Amy Chang, Jonathan Mitchell, Jennifer L. Alejo, Teresa P.Y. Chiang, Aura T. Abedon, Jake D. Kim, Robin K. Avery, Aaron A.R. Tobian, Macey L. Levan, Daniel S. Warren, Jacqueline M. Garonzik-Wang, Allan B. Massie, Dorry L. Segev, and William A. Werbel. Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved: Amy Chang, Jonathan Mitchell, Jennifer L. Alejo, Teresa P.Y. Chiang, Aura T. Abedon, Jake D. Kim, Robin K. Avery, Aaron A.R. Tobian, Macey L. Levan, Daniel S. Warren, Jacqueline M. Garonzik-Wang, Allan B. Massie, Dorry L. Segev, and William A. Werbel. The datasets generated during and/or analyzed during the current study are not publicly available but are available from the corresponding author on reasonable request. The datasets generated during and/or analyzed during the current study are not publicly available but are available from the corresponding author on reasonable request." @default.
• W4285087008 created "2022-07-14" @default.
• W4285087008 creator A5005410152 @default.
• W4285087008 creator A5015659265 @default.
• W4285087008 creator A5017487621 @default.
• W4285087008 creator A5025008545 @default.
• W4285087008 creator A5025830256 @default.
• W4285087008 creator A5030533822 @default.
• W4285087008 creator A5031986121 @default.
• W4285087008 creator A5043750897 @default.
• W4285087008 creator A5054162389 @default.
• W4285087008 creator A5057135761 @default.
• W4285087008 creator A5066564090 @default.
• W4285087008 creator A5069678834 @default.
• W4285087008 creator A5076022988 @default.
• W4285087008 creator A5088731656 @default.
• W4285087008 date "2022-07-19" @default.
• W4285087008 modified "2023-09-26" @default.
• W4285087008 title "Immunogenicity of Ad26.COV2.S prime and two subsequent doses of mRNA SARS‐CoV‐2 vaccines in solid organ transplant recipients: A case series" @default.
• W4285087008 cites W3197816628 @default.
• W4285087008 cites W4200248237 @default.
• W4285087008 cites W4200595269 @default.
• W4285087008 cites W4223913605 @default.
• W4285087008 cites W4225866313 @default.
• W4285087008 doi "https://doi.org/10.1111/ctr.14772" @default.
• W4285087008 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35822545" @default.
• W4285087008 hasPublicationYear "2022" @default.
• W4285087008 type Work @default.
• W4285087008 citedByCount "1" @default.
• W4285087008 countsByYear W42850870082023 @default.
• W4285087008 crossrefType "journal-article" @default.
• W4285087008 hasAuthorship W4285087008A5005410152 @default.
• W4285087008 hasAuthorship W4285087008A5015659265 @default.
• W4285087008 hasAuthorship W4285087008A5017487621 @default.
• W4285087008 hasAuthorship W4285087008A5025008545 @default.
• W4285087008 hasAuthorship W4285087008A5025830256 @default.
• W4285087008 hasAuthorship W4285087008A5030533822 @default.
• W4285087008 hasAuthorship W4285087008A5031986121 @default.
• W4285087008 hasAuthorship W4285087008A5043750897 @default.
• W4285087008 hasAuthorship W4285087008A5054162389 @default.
• W4285087008 hasAuthorship W4285087008A5057135761 @default.
• W4285087008 hasAuthorship W4285087008A5066564090 @default.
• W4285087008 hasAuthorship W4285087008A5069678834 @default.
• W4285087008 hasAuthorship W4285087008A5076022988 @default.
• W4285087008 hasAuthorship W4285087008A5088731656 @default.
• W4285087008 hasBestOaLocation W42850870082 @default.
• W4285087008 hasConcept C116675565 @default.
• W4285087008 hasConcept C126322002 @default.
• W4285087008 hasConcept C159047783 @default.
• W4285087008 hasConcept C168444539 @default.
• W4285087008 hasConcept C203014093 @default.
• W4285087008 hasConcept C2779134260 @default.
• W4285087008 hasConcept C2780868878 @default.
• W4285087008 hasConcept C2911091166 @default.
• W4285087008 hasConcept C3006700255 @default.
• W4285087008 hasConcept C3007834351 @default.
• W4285087008 hasConcept C3008058167 @default.
• W4285087008 hasConcept C3018513187 @default.
• W4285087008 hasConcept C524204448 @default.
• W4285087008 hasConcept C71924100 @default.
• W4285087008 hasConcept C8891405 @default.
• W4285087008 hasConceptScore W4285087008C116675565 @default.
• W4285087008 hasConceptScore W4285087008C126322002 @default.
• W4285087008 hasConceptScore W4285087008C159047783 @default.
• W4285087008 hasConceptScore W4285087008C168444539 @default.
• W4285087008 hasConceptScore W4285087008C203014093 @default.
• W4285087008 hasConceptScore W4285087008C2779134260 @default.
• W4285087008 hasConceptScore W4285087008C2780868878 @default.
• W4285087008 hasConceptScore W4285087008C2911091166 @default.
• W4285087008 hasConceptScore W4285087008C3006700255 @default.
• W4285087008 hasConceptScore W4285087008C3007834351 @default.
• W4285087008 hasConceptScore W4285087008C3008058167 @default.
• W4285087008 hasConceptScore W4285087008C3018513187 @default.
• W4285087008 hasConceptScore W4285087008C524204448 @default.
• W4285087008 hasConceptScore W4285087008C71924100 @default.
• W4285087008 hasConceptScore W4285087008C8891405 @default.
• W4285087008 hasIssue "9" @default.
• W4285087008 hasLocation W42850870081 @default.
• W4285087008 hasLocation W42850870082 @default.
• W4285087008 hasLocation W42850870083 @default.
• W4285087008 hasOpenAccess W4285087008 @default.
• W4285087008 hasPrimaryLocation W42850870081 @default.
• W4285087008 hasRelatedWork W3009669391 @default.
• W4285087008 hasRelatedWork W3036314732 @default.
• W4285087008 hasRelatedWork W3094132641 @default.
• W4285087008 hasRelatedWork W3127693599 @default.
• W4285087008 hasRelatedWork W4200329650 @default.
• W4285087008 hasRelatedWork W4205317059 @default.
• W4285087008 hasRelatedWork W4206669628 @default.
• W4285087008 hasRelatedWork W4210401150 @default.
• W4285087008 hasRelatedWork W4313274444 @default.
• W4285087008 hasRelatedWork W3127156785 @default.
• W4285087008 hasVolume "36" @default.
• W4285087008 isParatext "false" @default.
• W4285087008 isRetracted "false" @default.
• W4285087008 workType "article" @default.